Holen Sie sich die Stockscreener-App
2.68
2.90%
-0.08
Handel nachbörslich:
2.69
0.010
+0.37%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.84
24-Stunden-Volumen:
53,372
Relative Volume:
1.04
Marktkapitalisierung:
$4.83M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-27.83M
KGV:
-0.0132
EPS:
-203.7366
Netto-Cashflow:
$-26.98M
1W Leistung:
-8.84%
1M Leistung:
-39.37%
6M Leistung:
-59.76%
1J Leistung:
-92.81%
1-Tages-Spanne:
$2.5801
$2.85
1-Wochen-Bereich:
$2.5801
$3.01
52-Wochen-Spanne:
$2.5801
$48.78
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
2.68 | 4.97M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
Aptevo raises $4.5 million through warrant and equity financing - Investing.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan
Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds - Blockonomi
Aptevo raises $4.5M through warrant exercises and private placement By Investing.com - Investing.com South Africa
Aptevo raises $4.5M through warrant exercises and private placement - Investing.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Aptevo’s Common Warrants Cover Up to 4.3M Shares, Need Approval - Stock Titan
Aptevo Therapeutics says warrant holders exercise for cash at USD 4.03 per share - Bitget
Aptevo Therapeutics (APVO) Rises 1.49% to $4.08, Approaches Resistance at $4.28Wave Equality - dars.gov.et
Aptevo Therapeutics (APVO) Holds Near $4.01 as Trading Range Narrows Between Support and ResistanceVolume Rate Change - dars.gov.et
Aptevo Therapeutics (APVO) CMO converts RSUs; 156 shares withheld for taxes - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into 400 common shares - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into common shares - stocktitan.net
Aptevo Therapeutics (APVO) SVP SoYoung Kwon converts 638 RSUs to stock - Stock Titan
Aptevo Therapeutics (APVO) CFO exercises 638 RSUs into common stock - Stock Titan
Aptevo Therapeutics (APVO) director exercises RSUs, acquires 400 common shares - Stock Titan
Aptevo Therapeutics (APVO) director nets 400 common shares from RSU vesting - Stock Titan
Aptevo Therapeutics (APVO) Executive Chair exercises RSUs, withholds 406 shares for tax - Stock Titan
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics Inc expected to post a loss of $6.01 a shareEarnings Preview - TradingView
Aptevo Therapeutics (APVO) Slips 1.69% to $4.07 as Shares Hold Between Key Technical LevelsETF Inflow Streak - dars.gov.et
APVO Q2'26 Earnings: EPS estimate is (6.01) USD - tradingview.com
Aptevo Therapeutics Inc. SEC Filing (Jul 31, 2026) - Stock Titan
APVO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
APVO|Aptevo Therapeutics Inc|Price:4.180|Chg%:+0.110 - tradingkey.com
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo Dips on Credit Line - Baystreet.ca
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):